key: cord-0809320-2m5f9rqq authors: Megna, M.; Potestio, L.; Gallo, L.; Caiazzo, G.; Ruggiero, A.; Fabbrocini, G. title: Reply to “Psoriasis exacerbation after COVID‐19 vaccination: report of 14 cases from a single centre” by Sotiriou E et al. date: 2021-09-27 journal: J Eur Acad Dermatol Venereol DOI: 10.1111/jdv.17665 sha: 7b2ace796385f69ee6ee41d4f2d9eb16f23610f6 doc_id: 809320 cord_uid: 2m5f9rqq We have read with great interest the article recently published by Sotiriou et al.1 who reported 14 patients with psoriasis worsening after COVID-19 vaccination suggesting the possibility of the association between COVID-19 vaccines and psoriasis flares, especially in patients who do not receive any treatment for their psoriasis. Dear Editor, We have read with great interest the article recently published by Sotiriou et al. 1 who reported 14 patients with psoriasis worsening after COVID-19 vaccination suggesting the possibility of the association between COVID-19 vaccines and psoriasis flares, especially in patients who do not receive any treatment for their psoriasis. In our experience at the Dermatology Centre of the University of Naples Federico II, we observed 11 cases (8 male 72.7%, mean age 54.5 AE 8.9 years) of psoriasis exacerbation after COVID-19 vaccination with Pfizer mRNABNT162b2, Moderna mRNA-1273 or AstraZeneca-Oxford AZD1222 from February 2021 to July 2021 ( Table 2 . Interestingly, differing from Sotiriou et al, we observed 6 cases (54.5%) of psoriasis flares due to COVID-19 vaccine in subjects under biologic treatment. Among these, topical calcipotriol/betamethasone combination and/or phototherapy were added to current biologic treatment in 4 cases, while switching biologic agent was necessary in the remaining 2 patients. Although literature reported that COVID-19 vaccine does not seem to induce psoriasis flare in patients under biologics, 2,3 we observed a small percentage of subjects that experienced this flare nevertheless being under biologic treatment. To note, we want to highlight that they represent a very limited number of patients considering that more than 1200 psoriatic patients attending our Department are being treated with biologics for psoriasis and that currently about of 60% of Italian population is vaccinated. 4 As regards the treatment of the 5 remaining patients, biologic therapy or methotrexate was prescribed to 4 and 1 subjects after COVID-19 vaccine induced psoriasis worsening respectively. Our results show a highly percentage of psoriatic flare in male patients (8/11, 72.7%) suggesting male sex as a potential predictive risk factor. However, these data may be influenced by the fact that the majority of psoriasis patients attending our centre is male (68.9%). Previous concerns about the infectious risk of more severe COVID-19 infection in psoriatic subjects have been solved, 5 and the safety and effectiveness of COVID-19 vaccines has been showed, 6 also for these patients. 2, 3 In the literature, there are only few cases reporting the worsening of psoriasis after COVID-19 vaccine. 7-10 In our opinion, systemic treatment may reduce the risk of psoriasis flares after COVID-19 vaccination by the protection against the inflammatory process, which can cause the worsening of the disease. Hence, patients undergoing topical treatment for psoriasis have a higher risk of psoriatic flares compared with patients treated with systemic drugs. However, our experience showed that psoriasis exacerbation after COVID-19 vaccination may also develop in patients undergoing biologic treatment, even if the risk is reduced and limited. In conclusion, clinicians must keep in mind the possibility of psoriasis worsening after COVID-19 vaccine, regardless the mechanism of action of vaccines, advising patients to self-control their disease, especially within 14 days after vaccination, and to refer to clinicians if a worsening of the condition is noted. Being on biologic for psoriasis seems to strongly reduce but not to completely undo this risk. The patients in this manuscript have given written informed consent to publication of their case details. None. None. Matteo Megna: conceptualization, validation, visualization, writingoriginal draft preparation, writingreview and editing. Luca Potestio: data curation, formal analysis, investigation, visualization, writingoriginal draft preparation. Lucia Gallo: data curation, investigation, methodology, visualization, writingoriginal draft preparation. Giuseppina Caiazzo: data curation, formal analysis, validation. Angelo Ruggiero: data curation, validation, visualization, writingoriginal draft preparation. Gabriella Fabbrocini: conceptualization, validation, visualization, writingreview and editing, supervision. All authors read and approved the final version of the manuscript. Not required. Data are reported in the current study. AZD1222, AstraZeneca-Oxford AZD1222; mRNA-1273, Moderna mRNA-1273; mRNABNT162b2, Pfizer mRNABNT162b2; PASI, Psoriasis Area and Severity Index score at presentation in our department following the psoriasis flare. †Topical treatment and/or phototherapy added to biologic therapy. Psoriasis exacerbation after Covid-19 vaccination: report of 14 cases from a single center COVID-19 vaccination and patients with psoriasis under biologics: real-life evidence on safety and effectiveness from Italian vaccinated healthcare workers Safety and impact of Anti-COVID-19 vaccines in psoriatic patients treated with biologics: a real life experience Biologics for psoriasis patients in the COVID-19 era: more evidence, less fears Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape New onset of mainly guttate psoriasis after COVID-19 vaccination: a case report New onset of remitting seronegative symmetrical synovitis with pitting oedema and palmoplantar psoriasis flare-up after Sars-Cov-2 vaccination Exacerbation of psoriasis following COVID-19 vaccination in a patient previously treated with PD-1 inhibitor Psoriasis flare-up associated with second dose of Pfizer-BioNTech BNT16B2b2 COVID-19 mRNA vaccine